← FDA DRUG APPROVALS

FDA NDA · NDA018584

BECONASE

Sponsor: GLAXOSMITHKLINE

APPLICATION
NDA018584
TYPE
NDA
ORIGINAL APPROVAL
1981-09-30
LATEST ACTION
2002-12-16
ROUTE
NASAL
DOSAGE FORM
AEROSOL, METERED
MARKETING STATUS
Discontinued

Products

BECONASEDiscontinued
BECLOMETHASONE DIPROPIONATE 0.042MG/INH · AEROSOL, METERED · NASAL

Approval history

2002-12-16Labeling · Supplement 26 · standardLetterAP
2002-02-20Manufacturing (CMC) · Supplement 28 · standardAP
2001-08-31Labeling · Supplement 27 · standardLabelAP
1996-04-04Labeling · Supplement 25 · standardAP
1996-03-12Labeling · Supplement 23 · standardAP
1993-11-19Labeling · Supplement 18 · standardAP
1993-07-06Manufacturing (CMC) · Supplement 20 · standardAP
1992-08-10Manufacturing (CMC) · Supplement 19 · standardAP
1989-04-27Manufacturing (CMC) · Supplement 14 · standardAP
1988-12-15Labeling · Supplement 16 · standardAP
1988-02-24Labeling · Supplement 4 · standardAP
1988-02-16Manufacturing (CMC) · Supplement 1 · standardAP
1988-02-16Labeling · Supplement 2 · standardAP
1987-12-02Manufacturing (CMC) · Supplement 13 · standardAP
1987-03-06Manufacturing (CMC) · Supplement 12 · standardAP
1985-11-01Efficacy · Supplement 9 · standardAP
1985-11-01Labeling · Supplement 8 · standardAP
1985-10-04Manufacturing (CMC) · Supplement 10 · standardAP
1985-10-04Labeling · Supplement 11 · standardAP
1984-09-15Manufacturing (CMC) · Supplement 7 · standardAP
1984-03-01Manufacturing (CMC) · Supplement 5 · standardAP
1984-03-01Manufacturing (CMC) · Supplement 6 · standardAP
1981-09-30Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →